With Ranbaxy Under Belt, Sun Eyes Fast Track Global Growth
This article was originally published in PharmAsia News
Sun and Ranbaxy have finally combined into a single global company, but that could be just the beginning of a series of fresh challenges. Sun said it will look at growing its businesses faster than the industry average in most key markets, and at the same time look to remediate the troubled manufacturing sites of Ranbaxy. Management also indicated that it might not appeal against the recent U.S. Court ruling on generic Nexium.